World’s First Full-Service CRO for Nuclear Medicine

In 1996, ABX Advanced Biochemical Compounds was the first company to supply high-quality precursor compounds for molecular imaging, enabling the establishment of today's industrial production of PET radiopharmaceuticals. In 1998, recognizing the need for specialized expertise in the development of radiopharmaceuticals, ABX established its CRO division, which was spun off in 2002 to become ABX-CRO advanced pharmaceutical services, the world's first full-service CRO specializing in nuclear medicine.

ABX-CRO has been instrumental in many important product developments. A number of successful launches in recent years, such as amyloid or prostate imaging agents, have stimulated the development of new tracers by a growing number of players.

As an organization with its own scientific program, ABX-CRO conceived and launched the EANM initiative for multicenter nuclear medicine in 2006, became the first company in Europe to adopt quantitative SPECT reconstruction ("QSPECT") at the NCCCRI in Osaka in 2010 and launched ^QDOSE®, a clinical dosimetry software suite, in 2015. More recently, ABX-CRO has developed ^IDAC-alpha®, a clinical dosimetry tool to assess the effects of multiple alpha decays of nuclides such as radium-223, actinium-225 or thorium-227.

Due to its history, ABX-CRO has maintained a strong focus on oncology, neuroscience and imaging indications. Thanks to its particular interdisciplinary structure with a team of research physicians, pharmacologists, radiopharmacists, preclinical experts, imaging physicists and computer scientists, ABX-CRO is able to successfully conduct even the most unusual studies (e.g. imaging studies in psychiatric patients) with the same reliability as standard protocols.